Mentari Therapeutics (MTRI) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Savara is the larger company by market cap ($939.9 million vs $856.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTRI | SVRA |
|---|---|---|
| Share price | $14.70 | $4.26 |
| Market cap | $856.94M | $939.86M |
| 1-day change | -3.57% | -18.23% |
| YTD return | — | -29.35% |
| 1-year return | — | -13.41% |
| 5-year return | — | +270.43% |
| EPS (TTM) | — | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-118.84M |
| 52-week high | $23.30 | $7.01 |
| 52-week low | $5.75 | $4.00 |
| Distance from 52-week high | -36.91% | -39.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | — | +159.62% |
| Average volume | 19.42K | 2.79M |
| Shares outstanding | 58.30M | 220.62M |
| Employees | — | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mentari Therapeutics
MTRI stock →Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.
Health Care · Biotechnology: Pharmaceutical Preparations
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
MTRI vs SVRA FAQ
Which is bigger, Mentari Therapeutics or Savara?
Savara (SVRA) is larger, with a market capitalization of $939.86M compared with $856.94M for Mentari Therapeutics (MTRI).
Are Mentari Therapeutics and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.